The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
| Autor: | Shao-Wei Chen, Ann Wan-Chin Ling, Cze-Ci Chan, Yi-Wei Kao, Chien-Ying Huang, Pao-Hsien Chu, Yi-Hsin Chan |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
lcsh:Diseases of the circulatory (Cardiovascular) system medicine.medical_specialty Time Factors Databases Factual Endocrinology Diabetes and Metabolism Taiwan Heart failure Comorbidity Dipeptidyl peptidase-4 inhibitor Saxagliptin Lower risk Risk Assessment chemistry.chemical_compound Risk Factors Internal medicine Type 2 diabetes mellitus medicine Empagliflozin Humans Vildagliptin Dapagliflozin Sodium-Glucose Transporter 2 Inhibitors Original Investigation Aged Retrospective Studies Dipeptidyl-Peptidase IV Inhibitors business.industry Incidence Sodium glucose cotransporter-2 inhibitor Middle Aged Atrial fibrillation Treatment Outcome Diabetes Mellitus Type 2 chemistry lcsh:RC666-701 Sitagliptin Female Cardiology and Cardiovascular Medicine business Alogliptin medicine.drug |
| Zdroj: | Cardiovascular Diabetology, Vol 19, Iss 1, Pp 1-12 (2020) Cardiovascular Diabetology |
| DOI: | 10.21203/rs.3.rs-31689/v2 |
| Popis: | BackgroundSodium glucose cotransporter 2 inhibitor (SGLT2i) reduces the risk of hard cardiovascular endpoints in type 2 diabetes mellitus (T2DM) patients with/without established cardiovascular diseases. Whether SGLT2i is associated with a lower risk of new-onset atrial fibrillation (AF) in T2DM patients is unclear. We aimed to evaluate the risk of new-onset AF associated with the use of SGLT2i compared to dipeptidyl peptidase-4 inhibitor (DPP4i) among a longitudinal cohort of diabetic patients.MethodsWe used medical data from a multi-center healthcare provider in Taiwan, which included a total of 15,606 and 12,383 patients treated with SGLT2i and DPP4i, respectively, from June 1, 2016 to December 31, 2018. We used propensity-score weighting to balance covariates across study groups. Patients were followed up from the drug index date until the occurrence of new-onset AF, discontinuation of the index drug, or the end of the study period, whichever occurred first.ResultsOverall, 55%, 45%, and 0% of the patients were treated with empagliflozin, dapagliflozin, and canagliflozin, respectively. Most patients in the DPP4i group were prescribed with linagliptin (51%), followed by sitagliptin (24%), saxagliptin (13%), vildagliptin (8%) and alogliptin (5%). The use of SGLT2i was associated with a lower risk of new-onset AF compared with DPP4i after propensity-score weighting [hazard ratio: 0.61; 95% confidential interval: 0.50–0.73;P $$\ge$$≥8%, and chronic kidney disease. The advantage of SGLT2i over DPP4i persisted with different SGLT2i (dapagliflozin or empagliflozin) and either low- or standard-dose SGLT2i.ConclusionsSGLT2i was associated with a lower risk of new-onset AF compared with DPP4i among T2DM patients in real-world practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|